Acute Porphyria Drug Database

J01CR02 - Amoxicillin and Beta-Lactamase Inhibitor
Not porphyrinogenic
NP

Rationale
Ampicillin: Clinical experience as well as two references indicate non-porphyrinogenicity. The clavulanic acid component does probably not interact with CYPs and is stated in two references to be non-porphyrinogenic.
Chemical description
Ampicillin: Broadspectrum penicillin for parenteral use. Metabolized only to a slight extent to penicilloic acid, 72-92 % of the dose excreted unchanged. The antibiotic is combined with the betalactamase inhibitor clavulanic acid, which is extensively metabolized in the liver. No data pointing to CYP-interaction. Ampicillin: South African list: use. Australian list: safe. Clavulanic acid: South African list: use. Australian list: safe.
IPNet drug reports
Uneventful use reported in 51 patients with acute porphyria.

Similar drugs
Explore alternative drugs in similar therapeutic classes J01C / J01CR or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙